You can buy or sell Danaher and other stocks, options, ETFs, and crypto commission-free!
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following five segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Read More The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as to improve the aesthetics of the human smile. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.
Washington, District of Columbia
52 Week High
52 Week Low
Yahoo FinanceMay 23
CKHUY or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Diversified Operations stocks are likely familiar with Ck Hutchison Holdings Ltd (CKHUY) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Yahoo FinanceMay 20
Spiros Segalas Comments on Danaher
- By Holly LaFon Danaher (NYSE:DHR), a new position added during the quarter, is a diversified conglomerate whose subsidiaries design, manufacture, and market products and offer services geared to worldwide professional, medical and dental, industrial, and commercial markets. In February, the company announced that it is buying GE Life Sciences' biopharmaceutical business, a leading provider of instruments, consumables, and software that support the research, discovery, process development, and manufactu...
Seeking AlphaMay 16
GE asset sale to Danaher at risk amid weak life sciences market, analyst says
General Electric's (GE -1.6% ) deal to sell its Biopharma unit to Danaher (DHR +1.1% ) could be in jeopardy, says Gordon Haskett analyst John Inch, after some competitors posted weaker than expected quarterly results.
Expected Jul 18, Pre-Market